JP2015530983A - インターロイキン−１０融合タンパク質及びその使用 - Google Patents

インターロイキン−１０融合タンパク質及びその使用 Download PDF

Info

Publication number
JP2015530983A
JP2015530983A JP2015525845A JP2015525845A JP2015530983A JP 2015530983 A JP2015530983 A JP 2015530983A JP 2015525845 A JP2015525845 A JP 2015525845A JP 2015525845 A JP2015525845 A JP 2015525845A JP 2015530983 A JP2015530983 A JP 2015530983A
Authority
JP
Japan
Prior art keywords
fusion protein
antibody
seq
igg
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015525845A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015530983A5 (OSRAM
Inventor
リディア ジャスミン デュアナー，
リディア ジャスミン デュアナー，
トーマス エムリヒ，
トーマス エムリヒ，
イェンス フィッシャー，
イェンス フィッシャー，
ラルフ ホッセ，
ラルフ ホッセ，
エッケハルト メスナー，
エッケハルト メスナー，
パブロ ウマーニャ，
パブロ ウマーニャ，
タイケン シュイ，
タイケン シュイ，
Original Assignee
ロシュ グリクアート アーゲー
ロシュ グリクアート アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48917543&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2015530983(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ロシュ グリクアート アーゲー, ロシュ グリクアート アーゲー filed Critical ロシュ グリクアート アーゲー
Publication of JP2015530983A publication Critical patent/JP2015530983A/ja
Publication of JP2015530983A5 publication Critical patent/JP2015530983A5/ja
Priority to JP2018190250A priority Critical patent/JP6985232B2/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2015525845A 2012-08-08 2013-08-05 インターロイキン−１０融合タンパク質及びその使用 Pending JP2015530983A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2018190250A JP6985232B2 (ja) 2012-08-08 2018-10-05 インターロイキン−１０融合タンパク質及びその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12179709.6 2012-08-08
EP12179709 2012-08-08
PCT/EP2013/066342 WO2014023673A1 (en) 2012-08-08 2013-08-05 Interleukin-10 fusion proteins and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018190250A Division JP6985232B2 (ja) 2012-08-08 2018-10-05 インターロイキン−１０融合タンパク質及びその使用

Publications (2)

Publication Number Publication Date
JP2015530983A true JP2015530983A (ja) 2015-10-29
JP2015530983A5 JP2015530983A5 (OSRAM) 2016-09-29

Family

ID=48917543

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2015525845A Pending JP2015530983A (ja) 2012-08-08 2013-08-05 インターロイキン−１０融合タンパク質及びその使用
JP2018190250A Expired - Fee Related JP6985232B2 (ja) 2012-08-08 2018-10-05 インターロイキン−１０融合タンパク質及びその使用
JP2021009946A Withdrawn JP2021087426A (ja) 2012-08-08 2021-01-26 インターロイキン−１０融合タンパク質及びその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2018190250A Expired - Fee Related JP6985232B2 (ja) 2012-08-08 2018-10-05 インターロイキン−１０融合タンパク質及びその使用
JP2021009946A Withdrawn JP2021087426A (ja) 2012-08-08 2021-01-26 インターロイキン−１０融合タンパク質及びその使用

Country Status (22)

Country Link
US (2) US9346872B2 (OSRAM)
EP (1) EP2882774B1 (OSRAM)
JP (3) JP2015530983A (OSRAM)
KR (1) KR20150038012A (OSRAM)
CN (1) CN104540848B (OSRAM)
AR (1) AR092050A1 (OSRAM)
AU (1) AU2013301656A1 (OSRAM)
BR (1) BR112015002085A2 (OSRAM)
CA (1) CA2876285A1 (OSRAM)
CL (1) CL2014003605A1 (OSRAM)
CO (1) CO7151522A2 (OSRAM)
CR (1) CR20140565A (OSRAM)
EA (1) EA201500208A1 (OSRAM)
IL (1) IL236809A0 (OSRAM)
MA (1) MA20150232A1 (OSRAM)
MX (1) MX2015001675A (OSRAM)
PE (1) PE20150645A1 (OSRAM)
PH (1) PH12015500284A1 (OSRAM)
SG (1) SG11201408526SA (OSRAM)
TW (1) TW201418283A (OSRAM)
WO (1) WO2014023673A1 (OSRAM)
ZA (1) ZA201409304B (OSRAM)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017506075A (ja) * 2014-02-06 2017-03-02 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト インターロイキン−１０イムノコンジュゲート
JP2019505173A (ja) * 2015-12-04 2019-02-28 ノバルティス アーゲー 抗体サイトカイングラフト組成物および免疫調節のための使用方法
JP2020536512A (ja) * 2017-09-25 2020-12-17 ディンフー バイオターゲット カンパニー リミテッド タンパク性ヘテロ二量体及びその使用
JP2022536692A (ja) * 2019-06-11 2022-08-18 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド 調節不全の血漿カリクレインによって媒介される疾患の治療のための抗体のアデノ随伴ウイルスベクター送達
JP2022540187A (ja) * 2019-07-08 2022-09-14 プロジェン・カンパニー・リミテッド 新規融合タンパク質及びその用途
JP2022541156A (ja) * 2019-07-08 2022-09-22 プロジェン・カンパニー・リミテッド 新規ｉｌ－１０変異体タンパク質及びその用途
JP2023528721A (ja) * 2020-03-10 2023-07-06 ザ ユニバーシティ オブ ダンディー Ｉｌ－１０ムテイン
JP2023534847A (ja) * 2020-07-20 2023-08-14 デカ バイオサイエンシーズ， インコーポレイテッド Ｉｌ－１０を含む二重サイトカイン融合タンパク質
JP2023553934A (ja) * 2020-12-10 2023-12-26 ジョイント・ストック・カンパニー “バイオキャド” ヒトＩＬ－１０Ｒａ受容体を活性化するためのイムノサイトカインおよびその使用

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE036077T2 (hu) 2010-08-13 2018-06-28 Roche Glycart Ag Anti-FAP ellenanyagok és alkalmazásukra szolgáló eljárások
EP2673294B1 (en) 2011-02-10 2016-04-27 Roche Glycart AG Mutant interleukin-2 polypeptides
WO2013148117A1 (en) 2012-03-27 2013-10-03 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
US9161966B2 (en) 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
WO2014120619A2 (en) 2013-01-30 2014-08-07 Ngm Biopharmaceuticals, Inc. Compositions and methods of use in treating metabolic disorders
UA118028C2 (uk) 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
US20160250298A1 (en) 2013-11-01 2016-09-01 Spherium Biomed S.L. Inclusion bodies for transdermal delivery of therapeutic and cosmetic agents
CA3185180A1 (en) 2014-05-16 2015-11-19 Baylor Research Institute Methods and compositions for treating autoimmune and inflammatory conditions
ES2883158T3 (es) 2014-07-30 2021-12-07 Ngm Biopharmaceuticals Inc Composiciones y procedimientos de uso para el tratamiento de trastornos metabólicos
AP2017009828A0 (en) 2014-10-31 2017-03-31 Ngm Biopharmaceuticals Inc Compositions and methods of use for treating metabolic disorders
CN114634570B (zh) 2014-11-14 2025-05-06 豪夫迈·罗氏有限公司 包含tnf家族配体三聚体的抗原结合分子
CA2966776C (en) 2014-12-19 2021-05-04 Alkermes, Inc. Single chain fc fusion proteins
EP3277305B1 (en) 2015-03-31 2021-07-21 F. Hoffmann-La Roche AG Antigen binding molecules comprising a trimeric tnf family ligand
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
AU2016329120B2 (en) 2015-10-02 2023-04-13 F. Hoffmann-La Roche Ag Bispecific antibodies specific for a costimulatory TNF receptor
CN109068658A (zh) * 2015-11-18 2018-12-21 杜克大学 用于治疗癌症的肿瘤浸润淋巴细胞
CN106349393B (zh) * 2015-12-21 2020-10-30 合肥立方制药股份有限公司 一种增强抗体药物稳定性的结构
TWI897070B (zh) 2016-03-31 2025-09-11 美商恩格姆生物製藥公司 結合蛋白質及其使用方法
WO2018005226A2 (en) 2016-06-22 2018-01-04 Alkermes, Inc. Compositions and methods for modulating il-10 immunostimulatory and anti-inflammatory properties
CN112142859A (zh) * 2017-05-22 2020-12-29 杭州博虎生物科技有限公司 一种人白细胞介素10-Fc融合蛋白及其编码基因与应用
JOP20190271A1 (ar) 2017-05-24 2019-11-21 Novartis Ag بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة
US12006354B2 (en) 2017-05-24 2024-06-11 Novartis Ag Antibody-IL2 engrafted proteins and methods of use in the treatment of cancer
EP3688023B1 (en) * 2017-09-25 2025-08-27 Shihuida Pharmaceutical Group (Jilin) Co., Ltd. Methods and compositions for cancer treatment
WO2020023702A1 (en) 2018-07-25 2020-01-30 AskGene Pharma, Inc. Novel il-21 prodrugs and methods of use thereof
SG11202101779RA (en) 2018-08-30 2021-03-30 Hcw Biologics Inc Multi-chain chimeric polypeptides and uses thereof
EP4592314A3 (en) 2018-08-30 2025-11-05 ImmunityBio, Inc. Single-chain and multi-chain chimeric polypeptides and uses thereof
WO2020047333A1 (en) 2018-08-30 2020-03-05 HCW Biologics, Inc. Single-chain chimeric polypeptides and uses thereof
CN112955546B (zh) * 2018-11-26 2024-04-16 江苏恒瑞医药股份有限公司 一种人白细胞介素10变体及其衍生物
US11084857B2 (en) 2018-12-05 2021-08-10 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Nsp-interleukin-10 proteins and uses thereof
US20220144911A1 (en) * 2019-02-01 2022-05-12 Uab Research Foundation Methods and compositions for il10 signaling antagonism
US12006345B2 (en) 2019-02-21 2024-06-11 Xencor, Inc. Untargeted and targeted IL-10 Fc-fusion proteins
CN114072164A (zh) 2019-03-06 2022-02-18 德卡生物科学公司 Il-10变体分子和治疗炎性疾病和肿瘤的方法
CN111909276A (zh) * 2019-05-10 2020-11-10 复旦大学 一种融合蛋白及其用途
US11845801B2 (en) 2019-06-12 2023-12-19 AskGene Pharma, Inc. IL-15 prodrugs and methods of use thereof
CN114269903B (zh) 2019-06-21 2025-11-25 免疫生物公司 多链嵌合多肽和其用途
WO2021006603A1 (ko) * 2019-07-08 2021-01-14 주식회사 프로젠 신규 알러지 질환 치료용 약학적 조성물
CN112625137B (zh) * 2019-10-08 2021-10-08 北京东方百泰生物科技股份有限公司 一种人白细胞介素10-Fc融合蛋白及其医药用途
CN112618698B (zh) * 2019-10-08 2021-10-08 北京东方百泰生物科技股份有限公司 一种人白细胞介素10-Fc融合蛋白的注射制剂
JP7787812B2 (ja) 2019-11-25 2025-12-17 アルカームス インコーポレーテッド 置換大環状化合物および関連する治療方法
US20230087600A1 (en) * 2020-02-06 2023-03-23 Bristol-Myers Squibb Company Il-10 and uses thereof
AU2021220870A1 (en) 2020-02-11 2022-08-04 Immunitybio, Inc. Methods of treating age-related and inflammatory diseases
KR20220140572A (ko) 2020-02-11 2022-10-18 에이치씨더블유 바이올로직스, 인크. 조절 t 세포를 활성화시키는 방법
AU2021219720B2 (en) 2020-02-11 2025-10-02 Immunitybio, Inc. Chromatography resin and uses thereof
US12497462B2 (en) 2020-04-29 2025-12-16 Immunitybio, Inc. Anti-CD26 proteins and uses thereof
AU2021270563A1 (en) 2020-05-12 2022-12-15 Regeneron Pharmaceuticals, Inc. Novel IL10 agonists and methods of use thereof
KR20210141406A (ko) * 2020-05-14 2021-11-23 주식회사 프로젠 신규 재조합 융합단백질 및 그의 용도
US12024545B2 (en) 2020-06-01 2024-07-02 HCW Biologics, Inc. Methods of treating aging-related disorders
WO2021247003A1 (en) 2020-06-01 2021-12-09 HCW Biologics, Inc. Methods of treating aging-related disorders
KR20230031280A (ko) 2020-06-01 2023-03-07 에이치씨더블유 바이올로직스, 인크. 노화 관련 장애의 치료 방법
WO2022020324A1 (en) * 2020-07-20 2022-01-27 Viela Bio, Inc. Immunocytokines for treatment of autoimmune and inflammatory conditions
US11760747B2 (en) 2020-12-21 2023-09-19 Alkermes, Inc. Substituted piperidino compounds and related methods of treatment
KR20220099656A (ko) * 2021-01-07 2022-07-14 주식회사 프로젠 신규 il-10 변이체 융합단백질 생산용 세포주 및 그의 용도
WO2022165443A1 (en) * 2021-02-01 2022-08-04 AskGene Pharma, Inc. Chimeric molecules comprising an il-10 or tgf-beta agonist polypeptide
WO2023078245A1 (zh) * 2021-11-02 2023-05-11 广东菲鹏制药股份有限公司 Il10单体融合蛋白及其应用
EP4486368A1 (en) 2022-03-02 2025-01-08 ImmunityBio, Inc. Method of treating pancreatic cancer
CN118221829A (zh) * 2022-12-21 2024-06-21 广东菲鹏制药股份有限公司 一种il-10单体融合蛋白
WO2024144336A1 (ko) * 2022-12-30 2024-07-04 주식회사 프로젠 신규 이중 특이성 융합단백질 및 그의 용도
WO2024146463A1 (zh) * 2023-01-03 2024-07-11 深圳先进技术研究院 分泌白介素-10的细菌
WO2025137344A1 (en) 2023-12-20 2025-06-26 Bristol-Myers Squibb Company Antibodies targeting il-18 receptor beta (il-18rβ) and related methods

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008505174A (ja) * 2004-07-15 2008-02-21 ゼンコー・インコーポレイテッド 最適化Ｆｃ変異体
WO2010005389A1 (en) * 2008-07-11 2010-01-14 Forskarpatent I Syd Ab Oxidized ldl specific antibody-fusion and conjugated proteins
JP2011502137A (ja) * 2007-10-30 2011-01-20 フィロゲン エスピーエー 関節リウマチと関連する抗原

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1096187A (en) 1977-04-18 1981-02-24 Souhei Monden Ornament adapted to be fixed by permanent magnets
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1990005144A1 (en) 1988-11-11 1990-05-17 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
FI941572A7 (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
JPH08500962A (ja) 1992-02-06 1996-02-06 クリエイティブ バイオモレキュルズ，インコーポレイテッド 癌マーカー用生物合成結合蛋白質
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
ES2375931T3 (es) 1997-12-05 2012-03-07 The Scripps Research Institute Humanización de anticuerpo murino.
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
ES2248127T3 (es) 1999-10-04 2006-03-16 Medicago Inc. Metodo para regular la transcripcion de genes foraneos en presencia de nigtrogeno.
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
US7432063B2 (en) 2002-02-14 2008-10-07 Kalobios Pharmaceuticals, Inc. Methods for affinity maturation
KR101245983B1 (ko) 2004-03-31 2013-06-28 제넨테크, 인크. 인간화 항-ｔｇｆ-베타 항체
PL1737891T3 (pl) 2004-04-13 2013-08-30 Hoffmann La Roche Przeciwciała przeciw selektynie p
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
MX2008013575A (es) * 2006-05-08 2008-11-04 Philogen Spa Citoquinas dirigidas a anticuerpos para terapia.
CA2769619C (en) 2009-08-17 2019-04-30 Roche Glycart Ag Targeted immunoconjugates
HUE036077T2 (hu) 2010-08-13 2018-06-28 Roche Glycart Ag Anti-FAP ellenanyagok és alkalmazásukra szolgáló eljárások
KR20160044598A (ko) 2011-03-29 2016-04-25 로슈 글리카트 아게 항체 Fc 변이체
EA201892619A1 (ru) * 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
RU2016135788A (ru) 2014-02-06 2018-03-07 Ф.Хоффманн-Ля Рош Аг Иммуноконъюгаты интерлейкина 10

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008505174A (ja) * 2004-07-15 2008-02-21 ゼンコー・インコーポレイテッド 最適化Ｆｃ変異体
JP2011502137A (ja) * 2007-10-30 2011-01-20 フィロゲン エスピーエー 関節リウマチと関連する抗原
WO2010005389A1 (en) * 2008-07-11 2010-01-14 Forskarpatent I Syd Ab Oxidized ldl specific antibody-fusion and conjugated proteins

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
NARAMURA MAYUMI: "MECHANISMS OF CELLULAR CYTOTOXICITY MEDIATED BY A RECOMBINANT ANTIBODY-IL2 FUSION PROTEIN 以下省略", IMMUNOLOGY LETTERS, vol. V39 N1, JPN5015008710, 1 December 1993 (1993-12-01), NL, pages 91 - 99, ISSN: 0003594797 *
PENICHET MANUEL L.: "ANTIBODY-IL-2 FUSION PROTEINS: A NOVEL STRATEGY FOR IMMUNE POTENTIATION", HUMAN ANTIBODIES, vol. V8 N3, JPN5015008709, 1 January 1997 (1997-01-01), NL, pages 106 - 118, ISSN: 0003594796 *
ZHENG X. X.: "A NONCYTOLYTIC IL-10/FC FUSION PROTEIN PREVENTS DIABETES, BLOCKS AUTOIMMUNITY, 以下省略", THE JOURNAL OF IMMUNOLOGY, vol. V158 N9, JPN5015008711, 1 May 1997 (1997-05-01), US, pages 4507 - 4513, ISSN: 0003594795 *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017506075A (ja) * 2014-02-06 2017-03-02 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト インターロイキン−１０イムノコンジュゲート
JP2019505173A (ja) * 2015-12-04 2019-02-28 ノバルティス アーゲー 抗体サイトカイングラフト組成物および免疫調節のための使用方法
JP2021040637A (ja) * 2015-12-04 2021-03-18 ノバルティス アーゲー 抗体サイトカイングラフト組成物および免疫調節のための使用方法
JP2020536512A (ja) * 2017-09-25 2020-12-17 ディンフー バイオターゲット カンパニー リミテッド タンパク性ヘテロ二量体及びその使用
JP7356726B2 (ja) 2017-09-25 2023-10-05 ディンフー バイオターゲット カンパニー リミテッド タンパク性ヘテロ二量体及びその使用
JP2022536692A (ja) * 2019-06-11 2022-08-18 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド 調節不全の血漿カリクレインによって媒介される疾患の治療のための抗体のアデノ随伴ウイルスベクター送達
JP2022540187A (ja) * 2019-07-08 2022-09-14 プロジェン・カンパニー・リミテッド 新規融合タンパク質及びその用途
JP2022541156A (ja) * 2019-07-08 2022-09-22 プロジェン・カンパニー・リミテッド 新規ｉｌ－１０変異体タンパク質及びその用途
JP7497417B2 (ja) 2019-07-08 2024-06-10 プロジェン・カンパニー・リミテッド 新規ｉｌ－１０変異体タンパク質及びその用途
JP2023528721A (ja) * 2020-03-10 2023-07-06 ザ ユニバーシティ オブ ダンディー Ｉｌ－１０ムテイン
JP2023534847A (ja) * 2020-07-20 2023-08-14 デカ バイオサイエンシーズ， インコーポレイテッド Ｉｌ－１０を含む二重サイトカイン融合タンパク質
JP2023553934A (ja) * 2020-12-10 2023-12-26 ジョイント・ストック・カンパニー “バイオキャド” ヒトＩＬ－１０Ｒａ受容体を活性化するためのイムノサイトカインおよびその使用

Also Published As

Publication number Publication date
PE20150645A1 (es) 2015-05-11
EP2882774A1 (en) 2015-06-17
JP2019033755A (ja) 2019-03-07
BR112015002085A2 (pt) 2017-12-19
EA201500208A1 (ru) 2015-07-30
EP2882774B1 (en) 2018-10-03
AR092050A1 (es) 2015-03-18
TW201418283A (zh) 2014-05-16
HK1209439A1 (en) 2016-04-01
MA20150232A1 (fr) 2015-07-31
US20160340413A1 (en) 2016-11-24
CR20140565A (es) 2015-02-12
CA2876285A1 (en) 2014-02-13
PH12015500284A1 (en) 2015-04-27
CN104540848A (zh) 2015-04-22
IL236809A0 (en) 2015-03-31
JP2021087426A (ja) 2021-06-10
CL2014003605A1 (es) 2015-04-06
CN104540848B (zh) 2019-05-31
AU2013301656A1 (en) 2015-01-15
JP6985232B2 (ja) 2021-12-22
WO2014023673A1 (en) 2014-02-13
US20140044674A1 (en) 2014-02-13
KR20150038012A (ko) 2015-04-08
SG11201408526SA (en) 2015-03-30
US10040843B2 (en) 2018-08-07
US9346872B2 (en) 2016-05-24
ZA201409304B (en) 2017-09-27
MX2015001675A (es) 2015-04-10
CO7151522A2 (es) 2014-12-29

Similar Documents

Publication Publication Date Title
JP6985232B2 (ja) インターロイキン−１０融合タンパク質及びその使用
JP2022095643A (ja) インターロイキン－１０イムノコンジュゲート
US11365232B2 (en) Interleukin-2 fusion proteins and uses thereof
TWI881476B (zh) 結合cd3之抗體
US20200317774A1 (en) Anti-human cd19 antibodies with high affinity
TW202116806A (zh) 結合nkg2d之抗體
JP2023538716A (ja) Ｃｄ３及びｃｄ１９に結合する抗体
HK1209439B (zh) 白介素-10融合蛋白及其用途
HK1227040A1 (en) Interleukine-10 immunoconjugates
HK40063378B (zh) 与cd3结合的抗体
HK40091593A (zh) 与cd3和folr1结合的抗体
HK40057663B (zh) 与cd3结合的抗体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160803

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160803

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170614

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170711

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171010

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171211

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180605